Clinical characteristics and treatment outcomes of secondary ocular adnexal lymphoma

Clin Exp Ophthalmol. 2023 Mar;51(2):154-161. doi: 10.1111/ceo.14189. Epub 2022 Nov 18.

Abstract

Background: To describe the clinical characteristics and treatment outcomes of secondary ocular adnexal lymphoma (OAL), and emphasise the impact of timely biopsy and systemic evaluation on the diagnosis and treatment.

Methods: The data of patients with secondary OAL in our hospital from January 2010 to June 2021 were retrospectively reviewed.

Results: A total of 54 patients (30 men and 24 women) were included in the study. The mean age at presentation was 60 years (median 62 years; range 37-83 years). The main symptoms included ocular mass (74%), periorbital swelling (43%), and proptosis (39%). The main histopathological types were mucosa-associated lymphoid tissue lymphoma (30%), diffuse large B-cell lymphoma (28%), and natural killer/T-cell lymphoma (18%). In particular, three patients exhibited different pathological types of ocular lymphoma compared to previously diagnosed systemic lymphoma. The most common site of ocular and systemic involvement was the orbit (85%) and lymph nodes (56%), respectively, and 25 (46%) patients had occult extraocular lesions. Additionally, the 5-year overall survival rate of the entire cohort was 56%, and significant differences were observed between the three main pathological types and stages of the disease (all p < 0.001).

Conclusions: Secondary OAL is a rare disease with a poor prognosis. That the disease is associated with a more aggressive pathological type is well established, indolent lymphoma is not uncommon. Furthermore, OAL and previously diagnosed systemic lymphoma may be pathologically distinct in some patients. Therefore, we recommend a prompt excision biopsy and a thorough systemic evaluation of patients with suspected OAL.

Keywords: clinical characteristics; ocular adnexa lymphoma; prognosis; secondary.

MeSH terms

  • Eye Neoplasms* / diagnosis
  • Eye Neoplasms* / therapy
  • Female
  • Humans
  • Lymphoma, B-Cell, Marginal Zone* / diagnosis
  • Lymphoma, B-Cell, Marginal Zone* / therapy
  • Male
  • Middle Aged
  • Orbital Neoplasms* / diagnosis
  • Orbital Neoplasms* / pathology
  • Orbital Neoplasms* / therapy
  • Retrospective Studies
  • Treatment Outcome